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Abstract 
Background: Late presentation (LP) at the time of HIV diagnosis is defined as presentation with AIDS whatever the 
CD4 cell count or with CD4 <350 cells/mm. The objective of our study was to assess the prevalence of non-infectious 
comorbidities (NICM) and multimorbidity among HIV-positive individuals with and without a history of LP (HIV + LP 
and HIV + EP, respectively), and compare them to matched HIV-negative control participants from a community-
based cohort. The secondary objective was to provide estimates and determinants of direct cost of medical care in 
HIV patients.
Methods: We performed a matched cohort study including HIV + LP and HIV + EP among people attending the 
Modena HIV Metabolic Clinic (MHMC) in 2014. HIV-positive participants were matched in a 1:3 ratio with HIV-negative 
participants from the CINECA ARNO database. Multimorbidity was defined as the concurrent presence of ≥2 NICM. 
Logistic regression models were constructed to evaluate associated predictors of NICM and multimorbidity.
Results: We analyzed 452 HIV + LP and 73 HIV + EP participants in comparison to 1575 HIV-negative controls. The 
mean age was 46 ± 9 years, 27.5% were women. Prevalence of NICM and multimorbidity were fourfold higher in the 
HIV + LP compared to the general population (p < 0.001), while HIV + EP present an intermediate risk. LP was associ-
ated with increased total costs in all age strata, but appear particularly relevant in patients above 50 years of age, after 
adjusting for age, multimorbidity, and antiretroviral costs.
Conclusions: LP with HIV infection is still very frequent in Italy, is associated with higher prevalence of NICM and 
multimorbidity, and contributes to higher total care costs. Encouraging early testing and access to care is still urgently 
needed.
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Background
The World Health Organization defines “late presen-
tation” (LP) as a new HIV diagnosis with concurrent 
acquired immunodeficiency syndrome (AIDS) defining 
events, whatever the CD4+ T cell count, or else a new 
human immunodeficiency virus (HIV) diagnosis with 
CD4+ count less than 350 cells/mm3 [1, 2]. LP is asso-
ciated with adverse outcomes, including shorter life 
expectancy [3–5], and may also impair the efficacy and 
tolerability of combined antiretroviral therapy (cART) [4, 
6]. Although most HIV-positive individuals who begin 
therapy with a CD4+ count above 200 cells/mm3 even-
tually achieve a CD4+ count >500 cells/mm3, those with 
LP are far less likely to ever experience a robust CD4+ 
cell gain [7]. LP has also been associated with enhanced 
risk for drug toxicities including anemia [8] and immune 
reconstitution inflammatory syndrome (IRIS) [9]. 
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Approximately 40–60% of new HIV diagnoses in Italy 
are made in the context of LP [10]. The Collaboration 
of Observational HIV Epidemiological Research Europe 
(COHERE) study observed a small decrease in LP across 
Europe from 57.3% in 2000 to 51.7% in 2010/11, suggest-
ing that the prevalence of LP remains stubbornly high 
over time [5].
Older age represents a consistent risk factor for LP 
[11–14], as a result of barriers to HIV testing among 
older adults at the individual, medical and public health 
policy levels [15, 16]. With an increasing number of peo-
ple being diagnosed with HIV at an older age, the asso-
ciation between older age and LP is becoming even more 
significant and it is important to understand how LP 
might affect the health of people aging with HIV.
Nevertheless, it is still unknown whether there is an 
association between LP and age-related non-infectious 
co-morbidities (NICM) among people living with HIV, 
including cardiovascular disease (CVD), hypertension, 
type 2 diabetes mellitus (T2DM), chronic kidney disease 
(CKD), and osteopenia/osteoporosis. These heterogene-
ous comorbidities recognize age and HIV disease as inde-
pendent risk factors, and tend to aggregate into complex 
multimorbidity (MM) patterns (usually defined as two or 
more NICM being present in the same individual at the 
same assessment).
The objective of our study was to assess the preva-
lence of NICM and MM among HIV-positive individu-
als with and without a history of LP, and compare them 
to matched HIV-negative control participants from a 
community-based cohort. The secondary objective was 
to provide estimates and determinants of direct cost of 
medical care in LP HIV patients.
Methods
The study took place at the multidisciplinary Modena 
HIV Metabolic Clinic (MHMC), which was initiated in 
2004 to assess longitudinal metabolic changes among 
people with HIV. As previously described [17, 18], 
patients undergo annual comprehensive assessments in 
multiple domains, including metabolic and endocrino-
logical variables, bone mineral density (BMD), organ 
function, and social factors.
In the past 10  years a gradual decline in LP was 
observed in people attending MHMC, similar to that 
found in other European countries [5, 14, 19]. In 2004 LP 
prevalence in our cohort was 87%, while in 2012 it was 
65% of the new patients.
The current cross-sectional study was performed 
using data from two groups of individuals with visits to 
the MHMC in 2014. One group were all patients iden-
tified with a history of LP at the time of HIV diagnosis 
(HIV + LP). The other were all patients without a history 
of LP, and were therefore early presenters (HIV + EP). LP 
was defined according to the WHO definition, as a new 
HIV diagnosis with concurrent AIDS defining events, 
whatever the CD4+ T-cell count, or else a new HIV diag-
nosis with CD4+ count less than 350 cells/mm3 [1, 2].
HIV + LP and HIV + EP participants were each matched 
in a 1:3 ratio, on age, sex, and race (all Caucasian) and 
geographical area of origin, to participants in a commu-
nity-based cohort of the general population, the CINECA 
ARNO database [18]. The ARNO Observatory is an on-
line, multi-centre observational database in which popula-
tion-based data is collected and epidemiological methods 
[20] are used to combine and aggregate large volumes 
of health and healthcare-related data for each individual 
patient. These data include primary care provider-gener-
ated medication prescriptions, inpatient hospital records 
and discharge, summaries, diagnostic laboratory tests and 
radiographic examinations. This information is linked to 
other sources of patient data (including vital statistics and 
patient demographics) in order to provide comprehensive 
tracking of clinical diagnoses and healthcare use trends 
throughout Italy. Lifestyle, anthropometric and metabolic 
data are not collected in the CINECA ARNO database. All 
CINECA ARNO participants included in this study did 
not have a diagnosis of HIV infection, and were therefore 
assumed to be HIV negative.
Outcomes
NICM diagnoses were based according the following 
criteria previously used in our studies [18]. The category 
of CVD included the following diagnoses: myocardial 
infarction, coronary artery disease, peripheral vascular 
disease, stroke, angina pectoris, coronary artery bypass 
grafting, and angioplasty. Among MHMC participants, 
diagnostic criteria for hypertension, T2DM, and CKD 
included, respectively, blood pressure measurements 
>140/90  mmHg over two consecutive measurements, 
fasting serum glucose levels >126  mg/dL and eGFR 
<60  ml/min using the modification of diet in renal dis-
ease (MDRD) estimating equation [21]. Drug tracing cri-
teria used to establish hypertension and T2DM diagnoses 
in both cohorts included current use of antihypertensive 
and hypoglycemic drugs. In the HIV-positive groups only 
we analyzed low bone mineral density (t-score <−2SD) 
using dual-energy X-ray absorptiometry (DXA).
Direct healthcare cost assessments
The cost of care analysis is referred to the economic point 
of view of the Italian public healthcare system, which 
offers drugs and health assistance free of charge to any 
HIV-positive patients. Direct healthcare costs were ret-
rospectively analyzed in the calendar year 2013, as previ-
ously described [22] using the following indicators:
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1. Hospital costs
 Hospitalization costs were calculated by collecting 
International Classification of Diseases, ninth edi-
tion (ICD9) codes in both cohorts. All hospitalization 
with a primary or secondary ICD-9 diagnosis codes 
including CVD, hypertension, T2DM, bone frac-
tures, and renal failure diagnosis were selected [23] 
(Additional file 1: Table S1).
2. Outpatient HIV medical care cost
 With the movement of HIV care into the outpa-
tient setting, it is not possible to evaluate the total 
cost of medical care using ICD9 codes. For outpa-
tient cares we attributed a mean patient care cost 
obtained by the most recent reference value, which 
was able to better define HIV related care cost in 
patient with cART. This estimate is adjusted for cur-
rent CD4 count strata, accounting 1381 USD/year 
for patients with CD4 <75 cell/mmc, 1241 USD/year 
for 76 < CD4 < 200 cell/mmc and 190 USD/year for 
CD4  >  201 cell/mmc [24] (Additional file  1: Table 
S1).
3. NICM medication costs
 NICM medication costs were calculated using 
pharmaceutical tracing by average wholesale prices 
obtained by National Pharmaceutical Prontuary of 
Agenzia Italiana del Farmaco (AIFA) [25].
4. cART medication costs
 cART medication cost were calculated using phar-
maceutical tracing, by average hospital-sale price.
We converted hospital cost and outpatient HIV medi-
cal care cost from USDs to euros using conversion rate at 
the 31th of December, 2014 [26]. Total cost was defined 
as the sum of mean of NICM-costs plus mean of HIV-
hospitalization costs plus mean of drug costs.
Statistical analysis
Comparisons among groups were performed using χ2 test 
for categorical variables with Bonferroni adjusted post 
hoc analyses (significance level fixed at p  <  0.017) and 
T-test or Mann–Whitney U-test for normally and non-
normally distributed continuous variables, respectively. 
The probability of MM was drawn in the three compara-
tive groups across age distribution using a logistic model. 
Univariate and multivariable logistic regression models 
were constructed to determine factors associated with LP 
using general population as reference after correction for 
sex and age (in years).
Considering the non-normal distribution of total costs, 
generalized linear models were constructed to evalu-
ate independent factors associated with total cost in the 
whole population and in the subgroup of HIV-infected 
patients, using inverse Gaussian family distribution.
The variables for regression analyses were chosen on 
the basis of their clinical relevance.
Statistical analyses were performed STATA Software 
package, Intercooled version 13 for Mac (StataCorp ltd, 
Collage Station, TX, USA).
Results
525 individuals presented to the MHMC with new HIV 
diagnosis in 2014: 452 (85%) were HIV  +  LP and 73 
(15%) were HIV + EP. These HIV-positive MHMC par-
ticipants were matched to 1575 HIV-negative CINECA 
ARNO participants. Overall mean age was 46 ± 9 years 
and 27.5% were women, being the same across study 
groups per matching criteria.
With regards to HIV patients all the HIV +  LP were 
on ART regimen, while 30.3% of HIV + EP had not yet 
started ARV.
Table 1 shows descriptive characteristics of the sample 
and their association with HIV  +  LP in comparison to 
HIV + EP.
NICM prevalence are reported in Fig.  1. A trend 
in higher prevalence of any NICM was observed in 
HIV  +  LP participants. With regard to MM the dif-
ference in prevalence reached significant levels when 
comparing HIV- and HIV + EP with HIV + LP (respec-
tively p < 0.001 and p < 0.001), being present in 11% in 
HIV + LP, 4% in HIV + EP and 3% in HIV-negative con-
trols, respectively.
According to our study hypothesis we explored the prob-
ability of NICM and MM across age distribution using 
a logistic model in the three comparative groups. CVD, 
T2DM and MM were significantly higher in HIV  +  LP 
when compared to both HIV + EP and HIV-negative par-
ticipants (p < 0.01 for all comparisons) (Fig. 2).
No difference was found in hypertension risk across 
age distribution in the three groups.
CKD and low BMD data were not available for com-
parison in the HIV-negative group, but a non-significant 
trend in higher prevalence was observed in HIV  +  LP 
when compared to HIV + EP, respectively 7.52 vs. 4.11%, 
p = 0.291 and 20.13 vs. 12.33%, p = 0.147.
In multivariable models including age and sex, we 
observed fourfold increased odds of MM in HIV +  LP 
participants compared to HIV-negative individuals 
(OR 4.3, 95% CI 2.8–6.7, p  <  0.001). On the contrary, 
HIV + EP was not a risk factor for MM when compared 
to HIV-negative (OR 1.5, 95% CI 0.4–5.5, p  =  0.503) 
(Fig. 3).
With regards to our secondary objective we estimated 
NICM related costs, HIV outpatient costs and cART 
costs in the 3 patient groups. Additional file  1: Figure 
S1 describes total costs across age strata and Fig. 4 also 
stratify HIV patients in EP and LP.
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A multivariable logistic regression was built to predict 
total cost in the whole population including clinically sig-
nificant covariates (Table 2).
A second linear regression model was built to iden-
tify independent predictors of total cost in HIV-infected 
patients only. Predictors of total cost in cases were: LP 
(β, 2994; CI 1561–4427, p  <  0.001); MM (β, 7818; CI 
5653–9985, p < 0.001); age (β, 150; CI 87–212, p < 0.001); 
current CD4 count  <  200 (β, 2723; CI −270 to 5716, 
p = 0.075); male sex (β, 281; CI −865 to 1427, p = 0.630); 
protease inhibitors (PIs) exposure in months (β, 33; CI 
6–60, p = 0.015).
Discussion
Data from MHMC cohort study show that individu-
als with late presentation for HIV diagnosis (HIV + LP) 
exhibit an increased risk for age-related NICM and MM 
compared to individuals with early presentation for HIV 
diagnosis (HIV  +  EP) and matched HIV-negative indi-
viduals sampled from the general population. This dif-
ference translates into increased total costs of medical 
care in all age strata, but appear particularly relevant in 
patients above the age of 50. Therefore, LP influences 
both clinical and economical outcomes.
At any age, the risk for individual NICM as well as MM 
was fourfold higher in HIV  +  LP compared to people 
without HIV, while HIV + EP had an intermediate risk.
Our results should be interpreted with caution, in par-
ticular with regard to reproducibility of our results in dif-
ferent HIV settings. It could be argued that the tertiary 
referral setting of the MHMC may concentrate patients 
with higher prevalence of NICM and MM, however the 
prevalence of these conditions has previously been dem-
onstrated to be similar between local MHMC attend-
ees and those referred from other centers [18]. In Italy, 
Table 1 Demographic, anthropometric and metabolic characteristics associated with late presentation
All HIV + Patients  
(n = 525)
HIV + LP  
(n = 452)
HIV + EP  
(n = 73)
OR (95% CI) p value
Men (n) 381 (72.5%) 319 (71.2%) 60 (82.2%) 0.59 (0.28–1.00) 0.050
Age (mean, SD) 46 (±9) 46 (±8) 43 (±10) 1.03 (1.01–1.08) 0.010
Current CD4 (n/microL) (median, IQR) 590 (441–756) 570 (423–729) 750 (589–981) 0.997 (0.996–0.998) <0.001
Smoke
 None 318 (60.6%) 282 (62.4%) 36 (49.3%) 1 (ref.) –
 <10 cigs (moderate) 76 (14.4%) 63 (14.0%) 13 (17.8%) 0.61 (0.31–1.23) 0.173
 >10 cigs (intense) 99 (18.9%) 84 (18.6%) 15 (20.6%) 0.71 (0.37–1.37) 0.311
 Missing 32 (6.1%) 23 (5.1%) 9 (12.3%) Not included
BMI (kg/m2) (SD) 24.7 (±4.7) 24.7 (±4.7) 24.8 (±4.7) 0.99 (0.94–1.05) 0.891
Waist circompherence (cm) (SD) 89.1 (±12) 89.2 (±12) 88.6 (±12) 1.08 (0.98–1.03) 0.467
Lipodystrophy
 No lipodystrophy 184 (35.0%) 144 (31.9%) 40 (54.8%) 1 (ref.) –
 Lipoatrophy 129 (24.6%) 112 (25.0%) 16 (21.9%) 1.96 (1.04–3.68) 0.036
 Fat accumulation 212 (40.4%) 195 (43.1%) 17 (23.3%) 3.18 (1.73–5.84) <0.001
Cardiovascular and metabolic
 Triglycerides (mg/dL) (medican, IQR) 142 (95–207) 143 (96–209) 127 (93–185) 1.00 (0.99–1.00) 0.494
 Total cholesterol (mg/dL) (mean, SD) 198 (±45) 197 (±45) 197 (±43) 1.00 (0.99–1.00) 0.929
 HDL (mg/dL) (mean, SD) 46 (±14) 46 (±14) 47 (±16) 0.99 (0.98–1.00) 0.645
 LDL (mg/dL) (mean, SD) 117 (±33) 117 (±33) 119 (±33) 0.99 (0.99–1.00) 0.710
 Glucose (mg/dL) (mean, SD) 94 (±19) 95 (±21) 90 (±10) 1.03 (1.01–1.05) 0.011
 HOMA (median, IQR) 2.4 (1.4–3.8) 1.9 (1.2–2.9) 1.9 (1.2–3.0) 1.29 (1.09–1.54) 0.003
Fig. 1 NICM and MM prevalence distribution across study groups
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people with HIV have full free access not only to cART 
but also to clinical care including diagnostic procedures 
with no co-pay. This might result in a selection bias as 
screening activities are offered relatively more frequently 
to individuals with HIV than the general population, 
which might result in higher rates of incidentally identi-
fied asymptomatic disease. The information available in 
the CINECA-ARNO administrative database limited 
further comparisons in rates of NICM diagnoses, as not 
all major risk factors for NICM are collected and clini-
cal assessments are not provided. Moreover, with regard 
to CKD, the number of clinical events was very limited 
and BMD measurements were not available in CINECA 
cohort. Furthermore, the HIV  +  EP group is relatively 
small. Finally, the cross-sectional design of our study can-
not prove causality regarding the impact of LP on NICM 
or MM risk, nor we were able to collect biomarkers of 
systemic and tissue inflammation to argue a pathogenic 
link between LP and these outcomes.
The total cost of medical care was higher in HIV-pos-
itive participants than in the general population in any 
age strata. Higher costs was, as expected, mainly attribut-
able to antiretroviral drugs costs, especially PIs [27–29]. 
Of interest, total and ART costs for the HIV + EP group 
aged less than 40  years is much lower than the other 
HIV + EP strata. This can be explained with the fact that 
30.3% of these patients were not on ART, following WHO 
2013 guidelines [30].
Fig. 2 Age-related risk probability for CVD, T2DM and MM
Fig. 3 Multivariable logistic regression model to detect independent 
predictors of MM in the cohort
Fig. 4 Total and cART costs of medical care in HIV negative, HIV + EP 
and HIV + LP across age strata (mean)
Table 2 Independent predictors of total cost in the whole 
population
β-coeff 95% CI p value
HIV + EP vs. HIV− 1400 422–2380 0.005
HIV + LP vs. HIV− 3246 2233–4260 <0.001
Multimorbidity 6578 6049–7107 <0.001
Age 53 41–64 <0.001
Sex
 Women 0 (Ref ) – –
 Men 114 −106 to 334 0.309
ART 5606 4602–6610 <0.001
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Notably NICM-related care costs contributed signifi-
cantly to the higher cost burden of HIV-infected patients 
in the context of LP.
These findings reinforce what has already been sug-
gested by Krentz and Gill, that early initiation of ART 
may result in a cost-saving intervention [24]. Conversely, 
increasing age and concurrent MM represent a good 
indicator of increased total cost.
We believe that, in a demographic setting, particularly 
in a resource-rich setting, in which the majority of HIV-
infected patients are older than 50 years, total care cost 
will continue to increase [28, 31, 32].
These results suggest that, in the absence of targeted 
HIV prevention and diagnostic campaigns, the proportion 
of HIV+/LP will continue to increase, which will increase 
the burden of higher MM-related clinical and economic 
costs. In light of the unmistakable message recently pro-
vided by the strategic timing of antiretroviral therapy 
(START) study [33], which demonstrated a beneficial 
effect of immediate antiretroviral therapy for both serious 
AIDS-related and serious non–AIDS-related events, we 
can hope a reduction of the proportion of HIV + LP with 
a reduction in the burden and cost of comorbidities.
In conclusion, LP with HIV infection remains very 
common today in Italy and is associated with higher 
NICM and MM which is associated with higher total care 
costs. Promoting early testing and access to care is still 
urgently needed.
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